Oragenics receives NYSE American delisting notice; equity $3.7M below needed thresholds

ORAGENICS INC

NYSE American deficiency letter dated Aug 26, 2026 citing non-compliance with Sections 1003(a)(ii)/(iii); equity $3.7M at June 30, 2026 vs $4M/$6M minimums.
Compliance plan due Sept 25, 2026; cure period through Feb 25, 2028; OGEN shares get '.BC' (below compliance) designation.
Phase IIa trial for ONP-002: 9 participants dosed across 3 Australian sites (Alfred Health, Mackay, Royal Adelaide Hospital).
FDA Type B meeting responses received for July 2026 package; IND submission still targeted by end of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.